17 December 2018 | News
Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.
Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride (generic name, product name in the United States: BELVIQ, product name for once-daily formulation in the United States: BELVIQ XR, "lorcaserin") in Brazil to Eurofarma Laboratorios S.A. Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for sales in Brazil.
In October 2018, Eisai signed an agreement to grant exclusive development and marketing rights for lorcaserin in 17 countries in Latin America and the Caribbean, excluding Brazil.
Lorcaserin is an anti-obesity agent that is believed to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. Lorcaserin was approved in 2012 by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related co-morbid condition, and was launched in the United States in June 2013. Lorcaserin was approved in Brazil with the same indication as for the United States in December 2016.
By granting exclusive development and marketing rights for lorcaserin in Brazil to Eurofarma as well, Eisai aims to leverage Eurofarma's strong business foundation throughout Latin America to accelerate the delivery of lorcaserin to more patients.